VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
about
Intertwined regulation of angiogenesis and immunity by myeloid cellsControl of the immune response by pro-angiogenic factorsPaclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentThe role of immune checkpoint inhibition in the treatment of ovarian cancerCanonical and noncanonical Wnt proteins program dendritic cell responses for toleranceClinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Lymphangiogenesis and cancerVEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitroCancer prevention and therapy through the modulation of the tumor microenvironment.Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination.The angiogenic activity of ascites in the course of ovarian cancer as a marker of disease progressionKey Features of the Intragraft Microenvironment that Determine Long-Term Survival Following TransplantationNeuropilin 1: function and therapeutic potential in cancer.Immunological effects of chemotherapy and radiotherapy against brain tumors.The Unique Molecular and Cellular Microenvironment of Ovarian CancerBarriers to Radiation-Induced In Situ Tumor Vaccination.Angiogenesis inhibitors in tackling recurrent glioblastoma.Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.The role and significance of VEGFR2+ regulatory T cells in tumor immunityVEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.Antitumor immunity induced by VE-cadherin modified DC vaccine.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway.Targeting VEGF/VEGFR to Modulate Antitumor Immunity.[Impact of VEGF-A in exhaustion of intratumoral T cells].Autoantigen-Harboring Apoptotic Cells Hijack the Coinhibitory Pathway of T Cell ActivationUpdates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implicationsExploring immuno-regulatory mechanisms in the tumor microenvironment: Model and design of protocols for cancer remission
P2860
Q26830418-FDD0C095-AA36-4C9D-92D8-2DE16177192FQ27004733-903E5ABE-41FA-49E9-923E-D68A23A72FA6Q28073057-30D854D8-2084-4325-BF21-5FCBDE7A3FC3Q28077924-D3F8501A-86EE-448B-8A20-FC7577EC2E63Q28510103-01032D9A-3B87-4A16-A3C6-6C6EC7BA7200Q30412106-C5BFB03F-4661-41DA-9D56-DAA5AE0E5E9DQ34289358-F5584999-C8DB-40DD-92D5-0B44D4B0DA0EQ35064894-59BEF7DE-A4A6-4990-88C1-4577B8DA3AB7Q35954103-09758717-93BB-45E0-B17F-3230A0F83A48Q36137692-B2425D93-D9FD-4547-B79D-ACC8E8B23FA6Q36419140-697F403B-5285-4490-B76B-E43C5B4B90B9Q36842192-16057DD0-6D80-40F5-9CE6-62469F86DC69Q37058267-16C8792B-3706-467A-BAC7-C279182EEC62Q37247778-34E945F3-8CB6-4271-8898-8CC877F911D2Q37586773-A6A6B770-736A-4442-85BB-44DCCD161C57Q38008362-4B82396B-1F0A-4A98-AE4E-88CF899ECCF9Q38165001-2D074A37-175A-422A-8930-00D01F0DDD00Q38947116-EB664CD1-6AB0-4062-9BA0-4A1523F9C988Q39169603-755AA356-7F86-4EFA-9853-7801EB8081A7Q39203685-6DA7846C-81DD-4AED-9999-0B3DE7BCB5A0Q39259089-502BC2B6-F9A9-4ACB-B408-99B221417AD9Q40088326-01BD2861-6DC4-4C87-B5CB-2EA4D2B7884FQ41499942-2D3FAF8D-8BAE-4FFD-A37C-584E7A156B6DQ41738853-1BCB9A7F-7842-4C0F-AFC2-FABDB447DC0EQ42366549-4132202F-049B-4E48-A09E-CBC6DA016E5EQ47285613-94716DBA-5CFF-4C4E-AB58-43D6C2634F75Q48099660-91403F69-597A-49F7-89E6-D948E27E938CQ55008337-6B7D2D3C-AD08-461A-98F9-96965BFFD66CQ55056908-8D1F9DFE-7B52-415F-897A-C224085DD4BFQ57176332-7397C8A2-437D-44D5-A660-6C4AE511305AQ58760425-4FBA90DD-D875-49CE-AB0E-C532BB853B89Q58763679-A47D4FE4-DA4B-432D-BA35-9895777D111F
P2860
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
description
im Mai 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2011
@uk
name
VEGF directly suppresses activ ...... duals via VEGF receptor Type 2
@en
VEGF directly suppresses activ ...... duals via VEGF receptor Type 2
@nl
type
label
VEGF directly suppresses activ ...... duals via VEGF receptor Type 2
@en
VEGF directly suppresses activ ...... duals via VEGF receptor Type 2
@nl
prefLabel
VEGF directly suppresses activ ...... duals via VEGF receptor Type 2
@en
VEGF directly suppresses activ ...... duals via VEGF receptor Type 2
@nl
P2093
P2860
P356
P1476
VEGF directly suppresses activ ...... duals via VEGF receptor Type 2
@en
P2093
Alexandros Rodolakis
Apostolos C. Ziogas
Aristidis Antsaklis
Aristotle Bamias
Dimitrios Haidopoulos
Ekaterini Politi
Evangelos Terpos
George Vlahos
Marinos Tsiatas
Nikolaos Thomakos
P2860
P304
P356
10.1002/IJC.26094
P577
2011-05-25T00:00:00Z